1 citations,
January 2020 in “Egyptian Journal of Dermatology and Venereology” Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
11 citations,
May 2002 in “The Journal of Urology” Finasteride doesn't harm bone density in older men with BPH.
21 citations,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
35 citations,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
1 citations,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
110 citations,
April 2002 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.
9 citations,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
4 citations,
October 2002 in “BJUI” Finasteride treats hair loss but may affect prostate cancer detection.
April 2007 in “Nature Clinical Practice Urology” Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
1 citations,
May 2021 in “Mayo Clinic Proceedings” A 69-year-old man with sinus infection and fainting spells was diagnosed with a rare kidney disease, treated with steroids and a specific drug, which improved his condition.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
228 citations,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.
3 citations,
September 2000 in “Geriatric nursing” Aging men face unique health issues like erectile dysfunction, prostate problems, and baldness.
42 citations,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
8 citations,
December 2008 in “Journal of The American Academy of Dermatology” Finasteride can cause a unique skin reaction on the penile shaft.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
52 citations,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
28 citations,
August 2011 in “Journal of The American Academy of Dermatology” Early hair loss may indicate prostate issues.
20 citations,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
7 citations,
February 2016 in “Arab journal of urology” People with early hair loss may have a higher chance of enlarged prostate and metabolic syndrome, so they should be checked for urinary and metabolic issues.
98 citations,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.